Graves’ disease is an autoimmune disorder and the most common cause of hyperthyroidism. The pathophysiology of Graves’ disease is driven by thyroid-stimulating hormone receptor (TSHR) autoantibodies. While currently available therapies do not target these pathogenic autoantibodies, TSHR autoantibody levels may be used to predict response to treatment and patient outcomes. In this program, faculty will review the role of TSHR autoantibodies as the driver of Graves’ disease pathophysiology as well as the evidence supporting their value in predicting treatment outcomes. They will discuss the application and use of measuring and monitoring levels in clinical practice and how this may evolve in the future.
.jpg)
.jpg)